ProBio, a global Contract Development and Manufacturing Organization (CDMO), has appointed Allen Guo as Chief Executive Officer (CEO), Whitney Winters as Senior Vice President of U.S. Business Development, and Michael Vreeland as the U.S. Site Head and Interim Head of U.S. Process Development, effective December 1, 2024.
 
Dr. Li Chen, the previous CEO of ProBio, will remain as a consultant to ensure a smooth transition and on-going progress.
 
These leadership changes align with ProBio’s mission to accelerate life-changing therapies for biotech and pharmaceuticals to help patients in need.

Allen Guo, CEO

Guo joined ProBio in 2021, bringing 16 years of leadership and team-building experience at Janssen, Lonza, Becton Dickinson, and Patheon. Under his leadership, his business development team has contributed most of the company’s revenue by supporting clients’ end-to-end projects from the discovery phase through the pre-commercial Biologics License Application (BLA) stage, across multiple modalities. He has been at the heart of driving ProBio’s growth, securing milestone projects, and building high-performing teams.

Whitney Winters, SVP of U.S. Business Development

Winters joined ProBio earlier this year as Vice President of Commercial Excellence. She brings 17 years of experience in sales and marketing, with a successful tenure at West Pharmaceutical Services.
 
Known for her strategic expertise and execution excellence, Winters will lead both ProBio’s business development and marketing groups, ensuring a seamless integration of commercial strategies and tactics. Her expertise in market strategy, team leadership, and commercial excellence has already had an impact on ProBio’s ability to deliver on its vision of enabling transformative therapies and will allow her to lead the effort to expand ProBio’s presence and impact in the U.S. market.

Michael Vreeland, U.S. Site Head and Interim Head of U.S. Process Development

Vreeland joined ProBio as the US Site Head and Interim Head of Process Development, overseeing operations at the manufacturing facility in Hopewell, New Jersey, which serves ProBio’s North American hub for plasmid DNA and viral vector production. With over 16 years of cGMP manufacturing experience, including leadership roles at Curia, Thermo Fisher Scientific, and Sanofi Pasteur, Vreeland brings deep expertise in plasmid DNA, viral vectors, biologics manufacturing, and process development.
 
Li Zhu, Chairman of the Board of Directors of ProBio, said: “Allen, Whitney and Michael are uniquely qualified to lead ProBio into its next phase of growth. Their expertise and commitment to innovation and collaboration will ensure ProBio continues to empower our customers in delivering therapies that transform patients’ lives.”